 Michael Falta
Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Berylliosis | 15 | 2026 | 202 | 3.210 |
Why?
| | CD4-Positive T-Lymphocytes | 24 | 2026 | 1138 | 2.500 |
Why?
| | Beryllium | 12 | 2022 | 161 | 1.830 |
Why?
| | Chemokine CCL3 | 2 | 2026 | 26 | 1.620 |
Why?
| | HLA-DP beta-Chains | 10 | 2021 | 88 | 1.140 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 10 | 2017 | 333 | 0.950 |
Why?
| | Chemokine CCL4 | 2 | 2026 | 31 | 0.920 |
Why?
| | Epitopes, T-Lymphocyte | 3 | 2021 | 175 | 0.590 |
Why?
| | Lung | 11 | 2026 | 4103 | 0.580 |
Why?
| | HLA-DP Antigens | 3 | 2010 | 32 | 0.450 |
Why?
| | Lymphocyte Activation | 7 | 2011 | 1134 | 0.380 |
Why?
| | Receptors, Antigen, T-Cell | 5 | 2016 | 673 | 0.370 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 9 | 2000 | 24 | 0.340 |
Why?
| | Sarcoidosis | 2 | 2022 | 163 | 0.300 |
Why?
| | Mice, Transgenic | 5 | 2026 | 2189 | 0.290 |
Why?
| | T-Lymphocytes | 11 | 2016 | 1996 | 0.280 |
Why?
| | Peptides | 4 | 2026 | 993 | 0.270 |
Why?
| | Genetic Predisposition to Disease | 5 | 2016 | 2355 | 0.270 |
Why?
| | Chronic Disease | 7 | 2022 | 1816 | 0.260 |
Why?
| | Mice | 10 | 2026 | 18338 | 0.220 |
Why?
| | Disease Models, Animal | 4 | 2026 | 4559 | 0.220 |
Why?
| | Antibody Affinity | 1 | 2005 | 60 | 0.220 |
Why?
| | Genes, MHC Class II | 1 | 2005 | 76 | 0.220 |
Why?
| | Hybridomas | 4 | 2021 | 233 | 0.220 |
Why?
| | Dendritic Cells | 1 | 2026 | 499 | 0.190 |
Why?
| | Arthritis, Rheumatoid | 4 | 2005 | 1177 | 0.180 |
Why?
| | Aspergillus nidulans | 1 | 2021 | 6 | 0.170 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 3 | 2007 | 27 | 0.170 |
Why?
| | Animals | 12 | 2026 | 38141 | 0.170 |
Why?
| | Immunity, Innate | 2 | 2021 | 846 | 0.160 |
Why?
| | Azathioprine | 1 | 2000 | 44 | 0.160 |
Why?
| | Mutation | 9 | 2000 | 4093 | 0.160 |
Why?
| | Static Electricity | 2 | 2015 | 114 | 0.150 |
Why?
| | Bronchoalveolar Lavage Fluid | 4 | 2017 | 636 | 0.150 |
Why?
| | Molecular Sequence Data | 7 | 2015 | 2910 | 0.150 |
Why?
| | Antigens | 1 | 2021 | 349 | 0.150 |
Why?
| | Lung Diseases | 3 | 2022 | 783 | 0.150 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2014 | 407 | 0.140 |
Why?
| | Mice, Knockout | 1 | 2026 | 3125 | 0.140 |
Why?
| | Granuloma | 2 | 2022 | 97 | 0.140 |
Why?
| | Humans | 41 | 2026 | 145491 | 0.140 |
Why?
| | Macrophages | 1 | 2026 | 1509 | 0.140 |
Why?
| | Epitope Mapping | 2 | 2015 | 61 | 0.130 |
Why?
| | Amino Acid Sequence | 6 | 2013 | 2137 | 0.130 |
Why?
| | T-Lymphocyte Subsets | 1 | 1999 | 418 | 0.120 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2017 | 97 | 0.120 |
Why?
| | Amino Acid Motifs | 1 | 2015 | 220 | 0.110 |
Why?
| | Hypersensitivity | 2 | 2016 | 254 | 0.110 |
Why?
| | Peptide Library | 1 | 2013 | 91 | 0.100 |
Why?
| | Pulmonary Emphysema | 2 | 2006 | 277 | 0.100 |
Why?
| | Clone Cells | 9 | 2005 | 264 | 0.090 |
Why?
| | Complementarity Determining Regions | 1 | 2012 | 54 | 0.090 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2000 | 3917 | 0.090 |
Why?
| | Chagas Disease | 1 | 2012 | 42 | 0.090 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2012 | 226 | 0.090 |
Why?
| | Cell Line | 2 | 2016 | 2823 | 0.090 |
Why?
| | Autoantigens | 2 | 2005 | 426 | 0.080 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 17 | 0.080 |
Why?
| | Receptors, Cell Surface | 1 | 2013 | 372 | 0.080 |
Why?
| | Base Sequence | 6 | 2016 | 2180 | 0.080 |
Why?
| | Gene Expression | 1 | 2015 | 1478 | 0.080 |
Why?
| | Binding Sites | 1 | 2013 | 1313 | 0.080 |
Why?
| | Oligoclonal Bands | 2 | 2007 | 26 | 0.080 |
Why?
| | Genes, T-Cell Receptor beta | 2 | 2007 | 23 | 0.070 |
Why?
| | Colitis, Ulcerative | 1 | 2011 | 148 | 0.070 |
Why?
| | Synovial Fluid | 2 | 2000 | 68 | 0.070 |
Why?
| | Female | 19 | 2021 | 78763 | 0.070 |
Why?
| | Male | 17 | 2021 | 72817 | 0.070 |
Why?
| | Autoimmunity | 1 | 2014 | 936 | 0.070 |
Why?
| | Inflammation | 2 | 2022 | 2883 | 0.070 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2007 | 917 | 0.070 |
Why?
| | Gene Expression Regulation | 2 | 2014 | 2594 | 0.070 |
Why?
| | Adaptive Immunity | 2 | 2022 | 169 | 0.060 |
Why?
| | Crohn Disease | 1 | 2011 | 259 | 0.060 |
Why?
| | Poly I-C | 1 | 2006 | 58 | 0.060 |
Why?
| | Fluorescent Antibody Technique | 4 | 2011 | 364 | 0.060 |
Why?
| | Interferon-beta | 1 | 2006 | 92 | 0.060 |
Why?
| | Biliary Atresia | 1 | 2007 | 158 | 0.060 |
Why?
| | Interferon-alpha | 1 | 2006 | 194 | 0.060 |
Why?
| | HLA-DR Antigens | 1 | 2005 | 220 | 0.050 |
Why?
| | Antigen Presentation | 1 | 2005 | 207 | 0.050 |
Why?
| | Adult | 15 | 2021 | 40707 | 0.050 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2006 | 239 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 2016 | 2373 | 0.050 |
Why?
| | Case-Control Studies | 3 | 2021 | 3619 | 0.050 |
Why?
| | Biomarkers | 2 | 2011 | 4283 | 0.050 |
Why?
| | Enzyme-Linked Immunospot Assay | 2 | 2014 | 37 | 0.050 |
Why?
| | Drug Resistance | 2 | 2000 | 146 | 0.040 |
Why?
| | Lactalbumin | 1 | 2001 | 2 | 0.040 |
Why?
| | Antigens, Fungal | 1 | 2021 | 28 | 0.040 |
Why?
| | Immunoglobulin G | 2 | 2021 | 890 | 0.040 |
Why?
| | HLA-DR3 Antigen | 1 | 2021 | 76 | 0.040 |
Why?
| | Forkhead Transcription Factors | 2 | 2014 | 207 | 0.040 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2001 | 86 | 0.040 |
Why?
| | Muramidase | 1 | 2001 | 66 | 0.040 |
Why?
| | Fungal Proteins | 1 | 2021 | 146 | 0.040 |
Why?
| | Crystallography, X-Ray | 2 | 2014 | 491 | 0.040 |
Why?
| | Models, Molecular | 3 | 2014 | 1614 | 0.040 |
Why?
| | Histocompatibility Testing | 2 | 2012 | 123 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2000 | 79 | 0.040 |
Why?
| | HLA-DR4 Antigen | 1 | 2000 | 74 | 0.040 |
Why?
| | Granuloma, Respiratory Tract | 1 | 1999 | 13 | 0.040 |
Why?
| | Middle Aged | 10 | 2021 | 36176 | 0.040 |
Why?
| | Aged | 9 | 2017 | 26125 | 0.040 |
Why?
| | Neoplasm Proteins | 1 | 2001 | 441 | 0.030 |
Why?
| | Cloning, Molecular | 1 | 1999 | 535 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2011 | 374 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2022 | 772 | 0.030 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 25 | 1 | 2017 | 5 | 0.030 |
Why?
| | Nerve Tissue Proteins | 1 | 2001 | 590 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2022 | 1212 | 0.030 |
Why?
| | Interferon-gamma | 2 | 2014 | 782 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2001 | 733 | 0.030 |
Why?
| | HLA-DRB1 Chains | 1 | 2017 | 110 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 3 | 2012 | 573 | 0.030 |
Why?
| | Emulsions | 1 | 2016 | 59 | 0.030 |
Why?
| | Peptide Fragments | 1 | 2000 | 693 | 0.030 |
Why?
| | Protein Structure, Secondary | 2 | 2010 | 366 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 1049 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2000 | 842 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2000 | 2060 | 0.030 |
Why?
| | Alleles | 2 | 2010 | 893 | 0.030 |
Why?
| | Gene Rearrangement, T-Lymphocyte | 1 | 1994 | 16 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2014 | 1156 | 0.030 |
Why?
| | Protein Binding | 2 | 2011 | 2250 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 1040 | 0.030 |
Why?
| | Adolescent | 5 | 2007 | 22485 | 0.030 |
Why?
| | Sister Chromatid Exchange | 1 | 1993 | 4 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 553 | 0.030 |
Why?
| | Sodium | 1 | 2014 | 198 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2016 | 468 | 0.020 |
Why?
| | Chromosome Aberrations | 1 | 1993 | 164 | 0.020 |
Why?
| | Interleukin-2 | 1 | 2014 | 440 | 0.020 |
Why?
| | Severity of Illness Index | 2 | 2011 | 2945 | 0.020 |
Why?
| | Spleen | 1 | 2014 | 511 | 0.020 |
Why?
| | Radioimmunotherapy | 1 | 1991 | 25 | 0.020 |
Why?
| | Lymphocytes | 1 | 1993 | 379 | 0.020 |
Why?
| | Disease Progression | 2 | 2011 | 2862 | 0.020 |
Why?
| | Immunophenotyping | 1 | 2012 | 320 | 0.020 |
Why?
| | Chromosome Deletion | 1 | 1991 | 126 | 0.020 |
Why?
| | Granulocytes | 1 | 2011 | 81 | 0.020 |
Why?
| | Carcinoma, Hepatocellular | 2 | 1994 | 372 | 0.020 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2012 | 365 | 0.020 |
Why?
| | Lesch-Nyhan Syndrome | 1 | 1990 | 3 | 0.020 |
Why?
| | Child | 3 | 2000 | 22680 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 161 | 0.020 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2010 | 82 | 0.020 |
Why?
| | CD3 Complex | 1 | 2010 | 112 | 0.020 |
Why?
| | Occupational Exposure | 1 | 1993 | 355 | 0.020 |
Why?
| | STAT3 Transcription Factor | 1 | 2011 | 205 | 0.020 |
Why?
| | DNA | 2 | 1993 | 1451 | 0.020 |
Why?
| | ROC Curve | 1 | 2011 | 619 | 0.020 |
Why?
| | Cells, Cultured | 3 | 2007 | 4127 | 0.020 |
Why?
| | Down-Regulation | 1 | 2011 | 616 | 0.020 |
Why?
| | Liver Neoplasms | 2 | 1994 | 779 | 0.020 |
Why?
| | Glutamic Acid | 1 | 2010 | 256 | 0.020 |
Why?
| | Prospective Studies | 1 | 2000 | 8039 | 0.020 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2007 | 20 | 0.020 |
Why?
| | Phosphorylation | 1 | 2011 | 1707 | 0.020 |
Why?
| | Antibodies, Antinuclear | 1 | 2006 | 62 | 0.020 |
Why?
| | Proteinuria | 1 | 2006 | 104 | 0.010 |
Why?
| | Lupus Nephritis | 1 | 2006 | 67 | 0.010 |
Why?
| | RNA, Messenger | 2 | 2011 | 2820 | 0.010 |
Why?
| | Kidney Glomerulus | 1 | 2006 | 128 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2129 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2005 | 273 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1047 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1511 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2010 | 2499 | 0.010 |
Why?
| | Antigens, CD | 2 | 2000 | 557 | 0.010 |
Why?
| | Prognosis | 1 | 2011 | 4323 | 0.010 |
Why?
| | Genotype | 1 | 2007 | 1853 | 0.010 |
Why?
| | Fatty Acid-Binding Protein 7 | 1 | 2001 | 4 | 0.010 |
Why?
| | Camelids, New World | 1 | 2001 | 9 | 0.010 |
Why?
| | Statistics as Topic | 2 | 1993 | 284 | 0.010 |
Why?
| | Blotting, Southern | 2 | 1991 | 84 | 0.010 |
Why?
| | Chickens | 1 | 2001 | 184 | 0.010 |
Why?
| | Solvents | 1 | 2001 | 114 | 0.010 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2001 | 79 | 0.010 |
Why?
| | Colorado | 1 | 2011 | 4572 | 0.010 |
Why?
| | Perforin | 1 | 2000 | 22 | 0.010 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2000 | 15 | 0.010 |
Why?
| | CD28 Antigens | 1 | 2000 | 59 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2001 | 563 | 0.010 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 1999 | 11 | 0.010 |
Why?
| | Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1999 | 21 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2000 | 177 | 0.010 |
Why?
| | Ligands | 1 | 2001 | 667 | 0.010 |
Why?
| | Sequence Analysis | 1 | 1998 | 35 | 0.010 |
Why?
| | Gene Frequency | 2 | 1990 | 483 | 0.010 |
Why?
| | Liver | 1 | 2007 | 1895 | 0.010 |
Why?
| | Cartilage | 1 | 2000 | 198 | 0.010 |
Why?
| | Infant, Newborn | 1 | 1990 | 6437 | 0.010 |
Why?
| | Temperature | 1 | 2001 | 681 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2000 | 335 | 0.010 |
Why?
| | Neoplasms | 1 | 1993 | 2897 | 0.010 |
Why?
| | Immunologic Memory | 1 | 2000 | 368 | 0.010 |
Why?
| | Collagen | 1 | 2000 | 453 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2000 | 496 | 0.010 |
Why?
| | Computer Simulation | 1 | 2001 | 1026 | 0.010 |
Why?
| | Thioguanine | 1 | 1994 | 18 | 0.010 |
Why?
| | Lymphoma, T-Cell | 1 | 1994 | 29 | 0.010 |
Why?
| | Hepatitis | 1 | 1994 | 43 | 0.010 |
Why?
| | Reference Values | 1 | 1994 | 797 | 0.010 |
Why?
| | Signal Transduction | 1 | 2006 | 5202 | 0.010 |
Why?
| | Infant | 1 | 2007 | 10064 | 0.010 |
Why?
| | Twins, Dizygotic | 1 | 1993 | 109 | 0.010 |
Why?
| | Rats | 1 | 2001 | 5581 | 0.010 |
Why?
| | Child, Preschool | 1 | 2007 | 11837 | 0.010 |
Why?
| | DNA, Neoplasm | 1 | 1991 | 158 | 0.010 |
Why?
| | Cell Differentiation | 1 | 1998 | 2045 | 0.010 |
Why?
| | Karyotyping | 1 | 1990 | 105 | 0.000 |
Why?
| | Autoimmune Diseases | 1 | 1994 | 469 | 0.000 |
Why?
| | Whole-Body Irradiation | 1 | 1990 | 74 | 0.000 |
Why?
| | Genes | 1 | 1990 | 226 | 0.000 |
Why?
| | Antigens, Surface | 1 | 1990 | 155 | 0.000 |
Why?
| | Gene Rearrangement | 1 | 1990 | 156 | 0.000 |
Why?
| | Heterozygote | 1 | 1990 | 313 | 0.000 |
Why?
| | Mutagenicity Tests | 1 | 1989 | 18 | 0.000 |
Why?
| | Aged, 80 and over | 2 | 1993 | 8326 | 0.000 |
Why?
| | Ovarian Neoplasms | 1 | 1994 | 595 | 0.000 |
Why?
| | Fetal Blood | 1 | 1990 | 325 | 0.000 |
Why?
| | Sex Factors | 1 | 1993 | 2110 | 0.000 |
Why?
| | Smoking | 1 | 1993 | 1468 | 0.000 |
Why?
| | Immunotherapy | 1 | 1990 | 667 | 0.000 |
Why?
| | Age Factors | 1 | 1993 | 3340 | 0.000 |
Why?
| | Phenotype | 1 | 1990 | 3157 | 0.000 |
Why?
| | Risk Factors | 1 | 1993 | 10874 | 0.000 |
Why?
|
|
Falta's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|